drugset / Trial / NCT02201030

Immunogenicity and Safety Study of NBP606 in Healthy Infants

NCT02201030

Phase 3 Completed 577 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will assess the immunogenicity and safety of primary vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.

Timeline

Start
2014-09-06
Primary completion
2016-10-21
Completion
2016-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject NBP606 Unknown Intramuscular
Comparator Prevnar 13 Vaccine Intramuscular